Accueil   Diary - News   All news Imaxio, new vaccine candidate

Imaxio, new vaccine candidate

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.


The clinical trial is being conducted at Southampton, the lead trial site, and Oxford. It is a dose escalation study, where amounts of the potential vaccine are increased. The study will assess the safety of the vaccine candidate in people and its ability to generate immune responses that inhibit the growth of malaria eggs in mosquitos, preventing transmission of malaria.


Read the press release